These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33719596)

  • 1. Multi-Timescale Rhythmicity of Blood Glucose and Insulin Delivery Reveals Key Advantages of Hybrid Closed Loop Therapy.
    Grant AD; Lewis DM; Kriegsfeld LJ
    J Diabetes Sci Technol; 2022 Jul; 16(4):912-920. PubMed ID: 33719596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.
    Emami A; Willinska ME; Thabit H; Leelarathna L; Hartnell S; Dellweg S; Benesch C; Mader JK; Holzer M; Kojzar H; Pieber TR; Arnolds S; Evans ML; Hovorka R
    Diabetes Technol Ther; 2017 Jul; 19(7):433-437. PubMed ID: 28463010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTEGRATED INSULIN PUMP AND CONTINUOUS GLUCOSE MONITORING TECHNOLOGY IN DIABETES CARE TODAY: A PERSPECTIVE OF REAL-LIFE EXPERIENCE WITH THE MINIMED
    Aleppo G; Webb KM
    Endocr Pract; 2018 Jul; 24(7):684-692. PubMed ID: 30048171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid Close-Loop Systems Versus Predictive Low-Glucose Suspend and Sensor-Augmented Pump Therapy in Patients With Type 1 Diabetes: A Single-Center Cohort Study.
    Lunati ME; Morpurgo PS; Rossi A; Gandolfi A; Cogliati I; Bolla AM; Plebani L; Vallone L; Montefusco L; Pastore I; Cimino V; Argenti S; Volpi G; Zuccotti GV; Fiorina P
    Front Endocrinol (Lausanne); 2022; 13():816599. PubMed ID: 35498423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.
    Stewart ZA; Wilinska ME; Hartnell S; O'Neil LK; Rayman G; Scott EM; Barnard K; Farrington C; Hovorka R; Murphy HR
    Diabetes Care; 2018 Jul; 41(7):1391-1399. PubMed ID: 29535135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial.
    Wheeler BJ; Collyns OJ; Meier RA; Betts ZL; Frampton C; Frewen CM; Galland B; Hewapathirana NM; Jones SD; Chan DSH; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; de Bock MI
    Acta Diabetol; 2022 Jan; 59(1):31-37. PubMed ID: 34453208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark.
    Roze S; de Portu S; Smith-Palmer J; Delbaere A; Valentine W; Ridderstråle M
    Diabetes Res Clin Pract; 2017 Jun; 128():6-14. PubMed ID: 28432898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid Closed-Loop Insulin Pump Technology Can Be Safely Used in the Inpatient Setting.
    Pelkey MN; Boyle ME; Long A; Castro JC; Cook CB; Thompson B
    Endocr Pract; 2023 Jan; 29(1):24-28. PubMed ID: 36400399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia.
    Anderson SM; Buckingham BA; Breton MD; Robic JL; Barnett CL; Wakeman CA; Oliveri MC; Brown SA; Ly TT; Clinton PK; Hsu LJ; Kingman RS; Norlander LM; Loebner SE; Reuschel-DiVirglio S; Kovatchev BP
    Diabetes Technol Ther; 2019 Jun; 21(6):356-363. PubMed ID: 31095423
    [No Abstract]   [Full Text] [Related]  

  • 13. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
    Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
    Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the Omnipod
    Cobry EC; Berget C; Messer LH; Forlenza GP
    Ther Deliv; 2020 Aug; 11(8):507-519. PubMed ID: 32723002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions.
    Grosman B; Ilany J; Roy A; Kurtz N; Wu D; Parikh N; Voskanyan G; Konvalina N; Mylonas C; Gottlieb R; Kaufman F; Cohen O
    J Diabetes Sci Technol; 2016 May; 10(3):708-13. PubMed ID: 26880389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home.
    Renard E; Farret A; Kropff J; Bruttomesso D; Messori M; Place J; Visentin R; Calore R; Toffanin C; Di Palma F; Lanzola G; Magni P; Boscari F; Galasso S; Avogaro A; Keith-Hynes P; Kovatchev B; Del Favero S; Cobelli C; Magni L; DeVries JH;
    Diabetes Care; 2016 Jul; 39(7):1151-60. PubMed ID: 27208331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Efficacy of the Hybrid Closed-Loop System.
    Usoh CO; Johnson CP; Speiser JL; Bundy R; Dharod A; Aloi JA
    J Diabetes Sci Technol; 2022 May; 16(3):659-662. PubMed ID: 33430621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol.
    de Bock M; McAuley SA; Abraham MB; Smith G; Nicholas J; Ambler GR; Cameron FJ; Fairchild JM; King BR; Geelhoed EA; Davis EA; O'Neal DN; Jones TW;
    BMJ Open; 2018 Aug; 8(8):e020275. PubMed ID: 30104309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: a systematic review and meta-analysis of randomized-controlled trials.
    Fang Z; Liu M; Tao J; Li C; Zou F; Zhang W
    J Endocrinol Invest; 2022 Mar; 45(3):471-481. PubMed ID: 34535888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
    Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
    Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.